BASF increases prices for pharmaceutical excipients and active ingredients

05-Apr-2011 - Germany

Effective April 1, 2011, BASF will increase the sales prices globally for all pharmaceutical excipients and active pharmaceuticals ingredients by at least 10% depending on the product group.

This price increase affects the entire excipients portfolio including the Kollidon®, Kollicoat®, Cremophor®, and Lutrol® brands. The affected active pharmaceutical ingredient (API) portfolio contains products like Ibuprofen, Caffeine, and Ephedrine.

Due to the continued rise in costs for raw materials, energy and labor this price increase has become necessary. All existing contractual obligations will be honored.

Other news from the department price development

Most read news

More news from our other portals

Last viewed contents

Evonik increases prices of pharmaceutical amino acids

Medivir Announces Positive 48-week Interim Data from TMC435 Hepatitis C Phase 2b ASPIRE Study in Treatment-Experienced Genotype-1 Patients

BASF increases prices for pharmaceutical excipients and active ingredients

Evonik increases prices of cGMP-grade amino acids

BASF increases prices for vitamin B2

Significant overall survival benefit observed with radium 223 in patients with castration-resistant prostate cancer

Revolutionary Pan-Genome Analysis of Lactic Acid Bacteria Unveils Promising Opportunities for Food Industry and Healthcare

Revolutionary Pan-Genome Analysis of Lactic Acid Bacteria Unveils Promising Opportunities for Food Industry and Healthcare

Siegfried begins construction of new large-scale production plant in Minden (DE) - Total investment of up to CHF 100 million

Siegfried begins construction of new large-scale production plant in Minden (DE) - Total investment of up to CHF 100 million

Merck Invests €70 million to Expand ADC Manufacturing for Novel Cancer Therapies - Triples manufacturing capacity to meet increased global demand for antibody-drug conjugates (ADCs)

Merck Invests €70 million to Expand ADC Manufacturing for Novel Cancer Therapies - Triples manufacturing capacity to meet increased global demand for antibody-drug conjugates (ADCs)

Lonza expands bioconjugation in Visp with two additional manufacturing suites

Lonza expands bioconjugation in Visp with two additional manufacturing suites

Waters Corporation Opens State-of-the-Art Precision Manufacturing Facility in Longbridge, UK - Waters triples manufacturing footprint while increasing precision machining and metrology capacity to support future growth

Waters Corporation Opens State-of-the-Art Precision Manufacturing Facility in Longbridge, UK - Waters triples manufacturing footprint while increasing precision machining and metrology capacity to support future growth

Enduro Genetics raises €12 million to unlock the future of scalable bioproduction - Patented cell reprogramming technology "addicts" cells to high production and integrates seamlessly into any microbial bioproduction host

Enduro Genetics raises €12 million to unlock the future of scalable bioproduction - Patented cell reprogramming technology "addicts" cells to high production and integrates seamlessly into any microbial bioproduction host